Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman Sells 442 Shares

Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman sold 442 shares of Glaukos stock in a transaction dated Thursday, May 2nd. The stock was sold at an average price of $105.69, for a total transaction of $46,714.98. Following the transaction, the chief financial officer now directly owns 52,090 shares in the company, valued at $5,505,392.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Glaukos Price Performance

Shares of NYSE GKOS opened at $104.95 on Tuesday. The stock’s 50-day moving average is $93.59 and its two-hundred day moving average is $83.34. The company has a debt-to-equity ratio of 0.78, a current ratio of 5.38 and a quick ratio of 4.68. The company has a market cap of $5.27 billion, a price-to-earnings ratio of -36.44 and a beta of 1.08. Glaukos Co. has a 1-year low of $54.38 and a 1-year high of $110.73.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.12). Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. The firm had revenue of $85.60 million during the quarter, compared to analyst estimates of $79.60 million. During the same period last year, the business earned ($0.59) EPS. The firm’s revenue was up 15.8% compared to the same quarter last year. Analysts forecast that Glaukos Co. will post -2.2 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on GKOS. Wells Fargo & Company upped their price objective on Glaukos from $103.00 to $110.00 and gave the company an “overweight” rating in a report on Thursday, May 2nd. Mizuho raised their price objective on Glaukos from $85.00 to $100.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Truist Financial reaffirmed a “buy” rating and issued a $125.00 target price (up previously from $120.00) on shares of Glaukos in a research report on Thursday, May 2nd. Stifel Nicolaus reiterated a “buy” rating and set a $110.00 price target on shares of Glaukos in a research report on Wednesday, April 3rd. Finally, Jefferies Financial Group raised shares of Glaukos from a “hold” rating to a “buy” rating and increased their price objective for the stock from $84.00 to $125.00 in a research report on Monday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, Glaukos presently has a consensus rating of “Moderate Buy” and an average price target of $108.64.

Hedge Funds Weigh In On Glaukos

Institutional investors and hedge funds have recently modified their holdings of the company. Commonwealth Equity Services LLC lifted its holdings in Glaukos by 20.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 5,582 shares of the medical instruments supplier’s stock worth $420,000 after buying an additional 959 shares during the last quarter. Xponance Inc. purchased a new stake in Glaukos during the third quarter worth approximately $208,000. Raymond James & Associates boosted its holdings in Glaukos by 18.9% in the third quarter. Raymond James & Associates now owns 12,898 shares of the medical instruments supplier’s stock valued at $971,000 after purchasing an additional 2,053 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Glaukos by 10.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,916 shares of the medical instruments supplier’s stock valued at $746,000 after purchasing an additional 898 shares during the last quarter. Finally, Mackenzie Financial Corp acquired a new stake in Glaukos during the third quarter worth approximately $203,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.